Investigating the association between IDH1 status and MMP-2 levels in grade II-III astrocytomas, patients with wildtype IDH1 tumors (wtIDH1, n = 10; mean: 106.0 ±4.0) tended to have higher MMP-2 intensity than patients with mutated IDH1 tumors (mIDH1, n = 7; mean: 97.9 ±3.2) (p = 0.17) (Fig 3B). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).